Treatment of a patient with acute myeloid leukemia with FLT3-ITD mutation

Abstract

Acute myeloid leukemia (AML) is an aggressive myeloid malignancy characterised by ineffective haematopoiesis. A hallmark of AML is an unusual cytogenetical and molecular diversity, which define the treatment and has a huge impact on the patient’s treatment response and overall survival. Mutations most commonly detected in AML are the one in FMS-like tyrosine kinase 3 gene (FLT3). We hereby present a case report of a patient with AML with FLT3-ITD mutation treated with standard induction and consolidation chemotherapy combined with midostaurin.